The relationship between the receptors for the Epstein-Barr virus (EBV) and the C3d fragment of complement was investigated at the molecular level. In the presence of cell-bound C3, virus binding was enhanced in EBV genome-carrying lines. An identical effect could be elicited by C3d at one-quarter the weight amount; C3b and methylamine-treated C3 had no effect on virus binding. The minimum concentration of C3 which produced significant enhancement was 25 ~g/ml. Virus binding increases were observed only after 20 min of complement-cell co-incubation. The response was not noted with EBV-negative lines and was independent of virus strain assayed (B95-8 and P3HR-1). These studies suggest that the binding sites for the two moieties are distinct, although they both involve the same cell surface complex. The two receptors are believed to display cooperativity.
INTRODUCTION
An association between the receptors for the Epstein-Barr virus (EBV) and the C3d component of complement has been demonstrated Yefenof et al., 1976 Menezes et al., 1976) . Many lines of evidence support this relationship. Initially, it was seen that the two receptors were coordinately expressed on a number of cell lines and fresh lymphocyte fractions (Einhorn et aL, 1978; Jondal et al., 1976) . Various sublines of the same original Burkitt's lymphoma-derived line, Jijoye, which vary in EBV receptor expression, presented an opportunity to investigate quantitatively co-expression; the results confirmed the association (Klein et al., 1978) . At the membrane level, it was observed that EBV receptors and C3 receptors co-cap , and that stripping of either moiety eliminated binding of the other . Recently, it was seen that the two receptors quantitatively co-segregate in somatic cell hybrids (J~nsson et al., 1982) .
The extent of receptor identity has not been established. Glaser et al. (1977) have constructed :~ Relative levels of virus binding compared to Raji cells (Jonsson et al., 1982; Wells et al., 1983) , with greater than 90~ of the cells demonstrating binding (Wells et al., 1981b) .
§ Relative levels of complement binding compared to Raji cells (J~nsson et al., 1982; Wells et al., 1983) , with greater than 85% of the cells demonstrating binding (Jonsson et al., 1982; A. Wells et al., unpublished results) .
II ND, Not done. ¶ Greater than 90~ bind complement, expressing both receptors; no measurement of relative levels was performed.
receptors, bound 70~ of untreated levels in a 10-fold excess of antiserum. The two moieties, EBV and C3d, are thus postulated to bind to distinct sites in a bifunctional receptor complex. In order to assess the relationship between these two sites, directly labelled components were employed, thereby avoiding artefacts introduced with indirect procedures.
METHODS

Cells and virus.
Cell lines, their origins, and receptor characteristics are listed in Table 1 . All cells were grown as suspension cultures at 37 °C (60~ humidity and 5~ CO2) in RPMI 1640 culture medium supplemented with 8~ foetal calf serum, penicillin (200 IU/ml), and streptomycin (100 ~tg/ml).
EBV-producer B95-8 and P3HR-1 cells served as the source of B and P virus, respectively. The virus was produced, harvested and purified as described previously Wells et al., 198la) . Virus was iodinated (12Sl) by the chloramine-T method, and re-purified by sequential Dextran T 10 (Pharmacia) gradient ultracentrifugations .
Virus binding assay. The radiolabelled virus binding assay was performed as described by Koide et al. (1981) . In the standard assay, iodinated virus (5000 ct/min) was incubated with cells in 1 ml of 1 ~ bovine serum albumin (BSA) in buffered salt solution (BSS). After 30 min incubation at room temperature, the cell suspension was applied to the top of 1 ml 10~ sucrose in BSS. This was centrifuged for 1 min at 9000g and washed with 1 ~ BSA in BSS. Binding to Raji cells served as the positive control while K562 and YAC were background controls. Maximal binding was defined as percentage of label bound at the plateau region of the derived curve; it was operationally determined at 107 cells. Various pre-and co-incubations modified the standard assay, and are described in the text. Complement components. Human complement component C3 was purified to homogeneity according to an unpublished method of A. Lundwall. Methylamination of human C3 was performed as described (Lundwall et al., 1982) . Tryptic C3b was prepared (Bokisch et al., 1969) and C3d was obtained from C3 digested with trypsin by methods to be described (G. Eggertsen, U. Hellman,/~. Lundwall & J. Sj6quist, unpublished method) .
In these experiments no distinction was made between the C3b and C3bi receptors, and thus will be referred to as the C3b/bi receptor. The C3d receptor was, however, considered separately.
RESULTS
EB V binding is enhanced in the presence of C3 and C3d
Raji cells were pre-incubated with C3 or its derived fragments before binding virions. Virus binding was enhanced in the presence of low levels of C3 (Fig. 1) . This effect was also noted with C3d preparations, but not with C3b or methylamine-treated C3 (MeC3). Increased binding could be elicited with as little as 12 ~g/ml C3. C3d at one-quarter the weight amount as C3 produced identical results. Similar results were noted with Daudi cells (data not shown).
Complement C3 and C3d incubation increased virus binding both in its maximal level and in rate (Fig. 2) . No change was noted in the virus charging curve in the presence of MeC3 or C3b. This situation was observed both with cells washed free of unbound C3 before addition of'virus, and with cells mock-washed (pelleted and resuspended). EDTA (10 mM), a bivalent cation chelator, and phenylmethylsulphonyl fluoride (3 raM), a protease inhibitor, did not alter these results. Furthermore, enhancement was noted with flesh sera from EBV-negative donors. If the estimated concentration of C3 in the serum was compared to purified C3, the extent of virus binding enhancement was similar in both incubations (data not shown). the P3HR-l-derived substrain . It was previously seen that polyvalent anti-C3 receptor sera did not affect virus binding to these lines (Wells et al., 1983) . Incubating with complement components also did not alter the binding profiles (Fig. 3) . However, C3 enhanced virus binding to Raji and Daudi cells regardless of the virus strain. This further suggests the distinct nature of the P-virus-tropic receptor, and the indiscriminate adsorption of the prototype receptor as exemplified by that on Raji and Daudi cells. (Table 1) were tested to determine whether C3 enhancement of virus binding to Raji cells constituted a special case (Fig. 4) . Daudi and Raji, both EBV DNAcarrying Burkitt's lymphoma (BL)-derived lines, are considered to express the prototype virus receptor . These lines reacted similarly in the presence of C3 and its derivatives. Ramos, B JAB and Lukes, EBV-negative BL lines, did not respond to any treatment (Fig.  4) . Molt-4, which expresses both complement and virus receptors, but fails to permit virus penetration (Menezes et al., 1977) , was also unaffected. Rael, an unusual IgG-expressing EBVcarrying BL line, demonstrated clear binding enhancement in the linear region of the virus charging curve (Fig. 4) . Statistically significant enhancement was not noted at maximal binding levels, as determined with excess C3 at the plateau region of the curve (75 gg C3, 107 cells) (data not shown). EBV-converted Ramos derivatives (Table 1) , which express only low levels of virus receptors (Wells et al., 1982a) , gave results similar to Rael.
Lack of enhancement with P-virus-tropic receptor
Effect of C3 on EB V binding to a spectrum of target cells Various cell lines
Kinetics of binding enhancement by C3
Raji cells and virus were co-incubated with C3 for various lengths of time (Fig. 5 ). Cells and virus were incubated without components in parallel. The binding kinetics of both populations were identical for the first few minutes, enhancement not being observed until after 20min. Alternatively, cells were pre-incubated for different lengths of time with complement, washed, and virus was added to determine whether the time lag represented a cellular or viral effect of complement. In all incubations a cell-complement incubation of greater than 10 min, and an overall time of 20 to 25 min was necessary for the increases to be elicited.
DISCUSSION
The host range of EBV is extremely limited; by and large only B-lymphocytes and their derivatives of human and certain primate origin can be infected by it (for review, see Epstein & Achong, 1979) . The distribution of EBV receptors corresponds to that of the C3d receptor. As such, it was postulated that a correlation exists between the two . Many investigations have supported the initial association. While the previous studies have established the presence of such a connection, only recently has the molecular nature of it been probed. Antibodies directed against cell-bound complement inhibit virus binding suggesting a close interaction. However, anti-C3 receptor serum, which completely eliminates C3 adsorption, only partially interferes with EBV binding (Wells et al., 1983) . Thus, we are faced with a receptor complex in which the two sites are closely linked but separate. Purified complement components were employed to examine the relationship further. Directly labelling virus and C3 components avoids steric artefacts introduced in the course of indirect visualizations. As the two binding sites seem to be close, this consideration is paramount. Pre-or co-incubation of cells and complement resulted in enhanced virus binding to EBV-carrying lines, regardless of the virus strain employed. This effect was observed with either C3 or C3d. Methylamine-treated C3, which is functionally analogous to C3b, and C3b had no effect on binding. All four of the components bound to Raji and Ramos, while only C3 and C3d specifically adsorbed to Daudi and B JAB cells (A. Wells et al., unpublished results) . As C3 and C3d bind to the C3d receptor, and can increase both the rate and maximal level of binding to Daudi cells, which express only this complement receptor, it is strongly suggested that any complement-mediated effect occurs via this site.
EBV-negative lines were unaffected by C3 treatments. Unfortunately, we were not able to assay these lines in the presence of C3d. Thus, it is quite possible that the lack of virus enhancement was due to a failure to process/accommodate adequately C3 into the C3d receptor. EBVpositive lines have greater cell surface protease activities (Schulz et al., 1980) which could effect complement binding. Preliminary data for the virus-converted Ramos derivatives suggested enhanced EBV binding in the presence of C3. However, owing to low EBV receptor levels, the statistical significance of the data was difficult to determine. The lack of increased binding to EBV-negative lines in the presence of C3 may reflect only a quantitative difference in the rate and/or extent of C3 processing (Praz & Lesavre, 1983) .
The results of kinetic experiments suggest that a time period is necessary for the increase in virus binding to occur. The results were difficult to interpret due to the compounding variables: cell-C3 recognition, bound-C3 processing, and virus-cell binding kinetics. Pre-incubation of the cells and complement suggested that this was a cell-mediated phenomenon. Co-incubation of virus and complement, followed by column separation, did not result in enhanced virus adsorption (data not shown). It is possible that the cellular event is increased receptor production, although this seems unlikely considering the incubation temperature (approx. 20 °C), the medium (BSS), and the time period (20 min). Another explanation may be accelerated receptor cycling in which the net result is surface accumulation. A simpler model proposes cooperative binding between two linked receptors.
Two observations must be reconciled: that EBV binding can be partially inhibited by anti-C3 receptor sera even in the absence of complement binding (Wells et al., 1983) , and that the presence of C3d may enhance virus binding. It may be postulated that C3 is present in the viral envelope and the virus binds via the molecule. This is unlikely to be the sole mode of viral adsorption as the two high molecular weight envelope glycoproteins are responsible for virion binding (Wells et al., 1982b) . Neither these nor the other envelope components have been identified as complement components or shown to cross-react with such. Along the same line of reasoning, it may be that C3 incorporates into the virion envelope via its metastable binding site, thus allowing a second receptor, the C3d receptor, to be recognized. However, preincubating complement with virus did not enhance binding, and C3d alone could elicit the noted response.
It is not difficult to propose a model for the EBV receptor-C3d receptor interaction. In the absence of C3 the virus binds via the combined efforts of two large glycoproteins, thereby implying a large acceptor complex as the cell surface receptor (Wells et al., 1982b) . The C3d receptor has also been shown to be a large complex Stein et al., 1981) . Thus, the association between the two need not occur at the active sites. The individuality of the binding sites has been suggested by results with two somatic cell hybrids which are able to be infected by EBV but fail to bind complement (Glaser et al., 1977) , by only partial inhibition of virus binding by anti-C3 receptor sera (Wells et al., 1983) , and by biopsy material which binds EBV and polyvalent anti-C3 receptor serum without absorbing C3 (our unpublished observations). Yet the binding sites are physically linked . Binding of C3 and C3d to the C3d receptor of EBV-carrying cells results in a greater affinity of the virus-cell interaction. This may be the result of conformational alterations, or second messenger processing.
The evidence suggests a large bifunctional receptor complex which cooperatively binds both EBV and C3d. This cooperativity may have important implications for virus infection via ligand-enhanced endocytosis, and as a regulator of the immune response (Kakiuchi & Mariuchi, 1981; Mariuchi & Kakiuchi, 1982; Taylor et al., 1977) . 
